Company
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
Position
Nurix Therapeutics seeks an experienced Senior Scientist to join the Analytical Development and Quality Control group. The Senior Scientist will lead analytical and QC activities in IND-enabling and early phase clinical studies. The Senior Scientist will develop analytical test methods, characterize drug substance and drug product attributes, identify and characterize technical risk, and collaborate in risk mitigation work. The Senior Scientist will oversee and execute analytical development, validation, and testing both internally and at external CDMO/CRO partners and author relevant sections of regulatory filings.
The ideal candidate must have expertise in chromatographic method development, stability studies, and phase-appropriate validation and control. The ideal candidate should have a record of contribution to first-in-human INDs and experience in vendor oversight..
This position is onsite at Nurix headquarters in Brisbane, CA.
Responsibilities:
Qualifications:
Fit with Nurix Culture and Values
Salary Range: $162K – $186K
Job details are sourced from the employer's original posting.
Open job postingAbout the company
Nurix Therapeutics is a biopharmaceutical company focused on developing a pipeline of innovative therapies for cancer and other challenging diseases. They utilize their proprietary drug discovery platform to target protein degradation pathways.